thiazoles has been researched along with febuxostat in 238 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (2.10) | 18.2507 |
| 2000's | 61 (25.63) | 29.6817 |
| 2010's | 168 (70.59) | 24.3611 |
| 2020's | 4 (1.68) | 2.80 |
| Authors | Studies |
|---|---|
| Higashino, K; Hiroishi, K; Moriwaki, Y; Nasako, Y; Takahashi, S; Yamakita, J; Yamamoto, T | 1 |
| Couch, RC; Griffin, TB; Hasegawa, M; Horiuchi, H; Komoriya, K; Kondo, S; Osada, Y | 1 |
| Fukushima, H; Hasegawa, M; Komoriya, K; Kondo, S; Osada, Y; Takahashi, K; Tsuchimoto, M | 1 |
| Fujimura, Y; Hada, T; Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsui, T; Tsutsumi, Z; Yamamoto, T | 1 |
| Horiuchi, H; Kaneko, H; Kasahara, Y; Komoriya, K; Ohta, T; Ota, M | 1 |
| Horiuchi, H; Kaneko, H; Kasahara, Y; Kobayashi, M; Komoriya, K; Kondo, S; Nishimura, S; Ota, M | 1 |
| Eger, BT; Kondo, S; Nishino, T; Okamoto, K; Pai, EF | 1 |
| Yamamoto, T | 1 |
| Bomalaski, JS; Clark, MA | 1 |
| Becker, MA; Hunt, B; Joseph-Ridge, N; Khosravan, R; Kisicki, J; MacDonald, P; Mulford, D; Wu, J | 1 |
| Hoshide, S; Hosoya, T; Ishikawa, T; Komoriya, K; Kubo, J; Ohno, I; Takahashi, Y; Tsuchimoto, M | 1 |
| Hoshide, S; Kamatani, N; Kobayashi, H; Komoriya, K; Kubo, J; Nakachi, T; Takeda, K; Tsuchimoto, M; Yamanaka, H | 1 |
| Becker, MA; Hase-Aoki, K; Horiuchi, H; Kasahara, Y; Kondo, S; Takano, Y; Zhao, L | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL | 1 |
| Schumacher, HR | 1 |
| Choy, G | 1 |
| Tomlinson, B | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Moreland, LW | 1 |
| Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Mayer, MD; Vernillet, L; Wu, JT | 1 |
| Chen, LX; Schumacher, HR | 2 |
| Lustberg, ME | 1 |
| Gelber, AC | 1 |
| Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT | 1 |
| Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT | 1 |
| Lee, SJ; Terkeltaub, RA | 1 |
| Ziegler, R | 1 |
| Finley, JM | 1 |
| Bache, RJ; Chen, Y; Hou, M; Hu, Q; Zhang, J; Zhao, L | 1 |
| Bruce, SP | 1 |
| Hershfield, MS; Sundy, JS | 1 |
| Abeles, AM; Pillinger, MH; Rosenthal, P | 1 |
| Grabowski, B; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT | 1 |
| Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Zhao, L | 1 |
| Hamlin, RL; Kijtawornrat, A; Lolly, JL; Roche, BM; Shemanski, D; Wessale, JL; Zhao, L | 1 |
| Avila-Casado, C; Bautista-García, P; Franco, M; Johnson, RJ; Nakagawa, T; Sánchez-Lozada, LG; Soto, V; Tapia, E; Vega-Campos, IP; Zhao, L | 1 |
| Nishino, T; Okamoto, K | 1 |
| Okamoto, K | 1 |
| Ichida, K | 1 |
| Hoshide, S; Kanou, M; Mukoyoshi, M; Muroga, H; Nishimura, S; Taniguchi, K; Umeda, S | 1 |
| Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Wessale, JL; Zhao, L | 1 |
| Becker, MA; Hunt, BJ; Joseph-Ridge, N; Lademacher, C; MacDonald, PA | 1 |
| Joseph-Ridge, N; Khosravan, R; Kukulka, MJ; Vernillet, L; Wu, JT | 1 |
| Hair, PI; Keating, GM; McCormack, PL | 1 |
| Schlesinger, N | 2 |
| Edwards, NL | 2 |
| Sundy, JS | 2 |
| Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Bache, RJ; Chen, Y; Hu, X; Lu, Z; Wessale, JL; Xu, X; Zhang, P; Zhao, L | 1 |
| Yu, KH | 1 |
| Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR | 2 |
| Kirkpatrick, P; Pascual, E; Sivera, F; Yasothan, U | 1 |
| Ban, I; Canivet, J; Itami, K; Yamaguchi, J | 1 |
| Traynor, K | 1 |
| Becker, MA; Chohan, S | 1 |
| Keenan, RT; Pillinger, MH | 1 |
| Lioté, F; Perez-Ruiz, F; Scavulli, J; Terkeltaub, R; Zelman, D | 1 |
| Pandor, A; Stevenson, M | 2 |
| Hall, HA; Poon, SH; Zimmermann, B | 1 |
| Hussar, DA | 1 |
| Ernst, ME; Fravel, MA | 1 |
| Belavic, JM | 1 |
| Jansen, TL; Reinders, MK | 1 |
| Grabowski, BA; Khosravan, R; Mulford, DJ; Vernillet, L | 1 |
| Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF | 1 |
| Bardin, T; Barskova, V; Doherty, M; Guerne, PA; Jansen, TL; Leeb, B; Pascual, E; Perez-Ruiz, F; Pimentão, J; Punzi, L; Richette, P; Tausche, AK; Uhlig, T; Zimmermann-Górska, I | 1 |
| Barrons, R; Love, BL; Snider, KM; Veverka, A | 1 |
| Bache, R; Chen, Y; Hu, X; Wessale, J; Xu, X; Zhang, P; Zhao, L | 1 |
| Julkunen, H; Konttinen, YT | 1 |
| Grabowski, B; Khosravan, R; Lademacher, C; Vernillet, L; Wu, JT | 1 |
| Burns, CM; Wortmann, RL | 1 |
| Singh, JA | 2 |
| Gao, LG; Hui, RT; Luo, F; Wen, D; Yao, XP; Zhang, L; Zhou, XL | 1 |
| Quillen, DM | 1 |
| Graser, E; Pope, RS; Zychowicz, ME | 1 |
| El-Zawawy, H; Mandell, BF | 1 |
| Gunawardhana, L; Hunt, B; Macdonald, PA; Whelton, A; Zhao, L | 1 |
| Stiefelhagen, P | 1 |
| Cohen, MG | 1 |
| Gray, CL; Walters-Smith, NE | 1 |
| Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL | 1 |
| Dubost, JJ; Mathieu, S; Soubrier, M | 1 |
| Freeman, BA; Hundley, NJ; Kelley, EE; Malik, UZ; Radi, R; Romero, G; Tarpey, MM | 1 |
| Doghramji, PP | 1 |
| Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA | 1 |
| Hu, Q; Kamdar, F; Lee, J; Mansoor, A; Zhang, J | 1 |
| El-Armouche, A; Emons, J; Wittköpper, K | 1 |
| Reid, G; Uh, M | 1 |
| Hosoya, T; Kamatani, N; Naoyuki, K; Tatsuo, H | 1 |
| Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H | 2 |
| Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M | 3 |
| Hosoya, T; Iwao, O; Ohno, I; Tatsuo, H | 1 |
| Bardin, T; Ottaviani, S; Richette, P | 1 |
| Chohan, S | 1 |
| Canivet, J; Itami, K; Komiyama, M; Muto, K; Yamaguchi, J; Yamamoto, T | 1 |
| Goldfarb, DS | 1 |
| Al-Geizawi, S; Doares, W; Farney, A; Kaczmorski, S; Rogers, J; Stratta, R; Winfrey, S | 1 |
| Kriegsmann, J; Lange, U; Müller-Ladner, U; Panzner, I; Tausche, AK | 1 |
| Bapodra, A; Jana, P; Kadivar, MH; Kushwah, D; Sharma, H; Sinha, PK | 1 |
| Adenwalla, HN; O'Connor, CR | 1 |
| Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA | 1 |
| Schmidt, BM; Wagner, AD | 1 |
| Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA | 1 |
| Das, P; Suresh, E | 1 |
| McLean, L; Naik, H; Palmer, R; Wu, JT | 1 |
| Chefo, S; Jackson, RL; MacDonald, PA; Wells, AF | 1 |
| Jutkowitz, E; Meltzer, M; Pizzi, LT | 1 |
| Inoue, K; Isaka, Y; Kaimori, J; Kawada, N; Matsui, I; Moriyama, T; Omori, H; Rakugi, H; Takabatake, Y; Ueda, Y; Yamamoto, R | 1 |
| Abeles, AM | 1 |
| Hande, A; Lukram, O; Parmar, S | 1 |
| Hunt, B; Jackson, RL; MacDonald, PA | 1 |
| Fujisaki, H; Furuta, T; Kikuchi, H; Leimkühler, S; Nishino, T; Okamoto, K | 1 |
| Duh, PD; Warnez, PM | 1 |
| Gunawardhana, L; Naik, H; Tsai, M; Wu, JT | 1 |
| Curiel, RV; Guzman, NJ | 1 |
| Asmahan, MI; Hilmi, BA; Rosman, A | 1 |
| Chen, X; Deng, P; Guo, L; Wang, H; Zhong, D | 1 |
| Richette, P | 1 |
| André, B; Bouquegneau, A; Delanaye, P; Dubois, BE | 1 |
| Gao, J; He, Z; Sun, Y; Wang, S; Zhang, P; Zhang, T | 1 |
| Manger, B | 1 |
| Chohan, S; Dabholkar, A; Hunt, B; Jackson, R; White, WB | 1 |
| Doghramji, PP; Mandell, BF; Pope, RS | 1 |
| Carey, JJ; Conway, R; Coughlan, RJ | 1 |
| Ding, L; Huang, NY; Huang, Y; Lin, YF; Liu, RJ; Liu, XX; Wang, SL; Xiao, HF; Yang, J | 1 |
| Isaka, Y; Kaimori, JY; Kawada, N; Kitamura, H; Moriyama, T; Rakugi, H; Takahara, S; Tsuda, H | 1 |
| Shafik, AN | 1 |
| Butani, L; Calogiuri, G; Di Leo, E; Ferrannini, A; Foti, C; Nettis, E | 1 |
| Herrero-Beites, AM; Perez-Ruiz, F | 1 |
| Keenan, RT | 1 |
| Lopez-Olivo, MA; Suarez-Almazor, ME; Tayar, JH | 1 |
| Alonso-Pacho, A; de la Puerta González-Quevedo, C; Fabregate-Fuente, M; Sabán-Ruiz, J | 1 |
| Akimoto, T; Horikoshi, R; Inoue, M; Kusano, E; Morishita, Y | 1 |
| Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W | 1 |
| Bottorff, MB; Gandhi, PK; Gentry, WM | 1 |
| Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A | 1 |
| Burnett, RJ; Davis, RP; Fink, GD; Garver, HS; Szasz, T; Watts, SW | 1 |
| Von Zingel, M | 1 |
| Hosoya, T; Kobayashi, S; Ogura, M | 1 |
| Bianchi, G; Borghi, C; Bortoluzzi, A; Cimmino, MA; D'Avola, GM; Desideri, G; Di Giacinto, G; Favero, M; Govoni, M; Grassi, W; Lombardi, A; Manara, M; Marangella, M; Matucci Cerinic, M; Medea, G; Minisola, G; Prevete, I; Punzi, L; Ramonda, R; Scirè, CA; Spadaro, A | 1 |
| Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I | 1 |
| Becker, MA; Hunt, BJ; Jackson, RL; MacDonald, PA | 1 |
| Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG | 1 |
| Inamadugu, JK; Katreddi, HR; Pilli, NR; Ramesh, M; Vaka, VR | 1 |
| Franklin, JM; Kim, SC; Liu, J; Schmidt, BM; Schneeweiss, S; Solomon, DH | 1 |
| Hu, XJ; Liu, J; ShenTu, JZ; Shi, Z | 1 |
| Roberts, J; Seifried, RM | 1 |
| Chefo, S; Goldfarb, DS; Gunawardhana, L; MacDonald, PA; McLean, L | 1 |
| Ohno, I | 1 |
| Fujimura, H; Honorat, JA; Kinoshita, M; Koda, T; Mochizuki, H; Nakatsuji, Y; Okuno, T; Sakoda, S; Shirakura, T; Tada, S; Takata, K | 1 |
| Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C | 1 |
| Busso, N; Ives, A; Nomura, J; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y | 1 |
| Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S | 1 |
| Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S | 1 |
| Dhakad, U; Dhaon, P; Wakhlu, A | 1 |
| Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH | 1 |
| Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N | 1 |
| Berns, JS; Wilson, FP | 1 |
| Stamp, LK | 1 |
| Hwang, SJ; Jang, HH; Jung, KH; Kim, W; Lee, HJ; Lee, KH; Lee, SR; Woo, JS | 1 |
| Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T | 1 |
| Adam, S; Krishna Reddy, RC; Raju, CN; Rasheed, S; Subba Rao, D; Venkata Rami Reddy, Y | 1 |
| Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X | 1 |
| Malik, S; Sahu, K; Shaharyar, M; Siddiqui, AA | 1 |
| Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT | 1 |
| Bégin, J; Doré, M; Frenette, AJ; Mansour, AM; Troyanov, Y | 1 |
| Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N | 1 |
| Bae, EJ; Chang, SH; Cho, HS; Jang, HN; Kang, Y; Kim, MJ; Park, DJ; Yun, S | 1 |
| Aoki, T; Hishida, M; Maekawa, M; Morinaga, T; Tamai, H; Tomida, H | 1 |
| Fuchinoue, S; Nakajima, I; Teraoka, S; Tojimbara, T; Yashima, J | 1 |
| Espinoza, LR; Grewal, HK; Martinez, JR | 1 |
| Akhras, KS; Hatoum, H; Khanna, D; Khanna, P; Lin, SJ; Shiozawa, A | 1 |
| Busso, N; Ives, A; Kobayashi, T; Matsui, C; Nomura, J; Shirakura, T; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y | 1 |
| Bocale, R; Desideri, G; Ferri, C; Grassi, D; Pontremoli, R | 1 |
| Becker, MA; Chaichian, Y; Chohan, S | 1 |
| Edwards, NL; So, A | 1 |
| Banse, C; Fardellone, P; Paccou, J | 1 |
| Jansen, TL | 1 |
| Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W | 1 |
| Chen, J; Fu, Y; Li, P; Mo, HY; Song, HP; Zhang, H; Zhang, M | 1 |
| Ohya, M; Shigematsu, T | 1 |
| Mounsey, A; Tillett, J; White, S | 1 |
| Arnadóttir, M | 1 |
| Hosoya, T; Kimura, K; Ohno, I; Shibagaki, Y | 1 |
| Ihm, CG; Jeong, KH; Kim, YG; Lee, HJ; Lee, SH; Lee, TW; Moon, JY; Sung, JY | 1 |
| Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y | 1 |
| Kim, HA; Seo, YI; Song, YW | 1 |
| Hayashi, H; Hayashi, T; Hikosaka, S; Mizuno, T; Murase, M; Nagamatsu, T; Shimabukuro, Y; Takahashi, K; Yamada, S; Yuzawa, Y | 1 |
| Deng, K; Jiang, X; Lv, G; Wang, L; Wang, Z; Xie, H | 1 |
| Brucato, AL; Corrao, S; Di Corato, P; Djade, CD; Franchi, C; Ghidoni, S; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M | 1 |
| Abdi-Ali, L; Benucci, M; Cera, I; Rossini, M; Sacco, S; Saviola, G | 1 |
| Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R | 1 |
| Choi, HK; Jutkowitz, E; Kuntz, KM; Pizzi, LT | 1 |
| Kataoka, H; Rock, KL; Yang, K | 1 |
| Ahuja, BK; Bagri, S; Jena, SK; Paidi, SK; Suresh, S | 1 |
| Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A | 1 |
| Dalbeth, N; Robinson, PC | 1 |
| Bridgeman, MB; Chavez, B | 1 |
| Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q | 1 |
| Li, G; Qiu, JB; Sheng, Y; Zhu, MR | 1 |
| Flipo, RN; Patrikos, DK; Richette, P | 1 |
| Li, L; Lu, W; Sun, Y; Zhou, TY | 1 |
| Chang, JY; Chin, SW; Chu, MT; Chung, WH; Huang, YL; Hung, SI; Pan, RY; Wang, WC | 1 |
| Kim, KA; Park, JY | 1 |
| Asano, T; Fujishiro, M; Fukushima, T; Kamata, H; Kanaoka, R; Katasako, A; Kushiyama, A; Matsunaga, Y; Mori, K; Nakatsu, Y; Sakoda, H; Seno, Y; Yamamotoya, T | 1 |
| Arava, S; Arya, DS; Bharti, S; Bhatia, J; Golechha, M; Krishnamurthy, B; Nag, TC; Rani, N; Ray, R | 1 |
| Day, RO; Furlong, TJ; Ghosh, D; McGann, PM | 1 |
| Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T | 1 |
| Bakinde, N; Mome, R | 1 |
| Filiopoulos, V; Hadjiyannakos, D; Vlassopoulos, D | 1 |
| Sircar, D | 1 |
| Michel, MC; Steubl, D | 1 |
| Andrés, M; Gil, S; Pascual, E; Quilis, N; Ranieri, L; Vela, P | 1 |
| Gunawardhana, L; White, WB | 1 |
| Bhattacharyya, S; Macklin, EA; Schwarzschild, MA | 1 |
| Bartsch, LA; Ortiz, A; Perez-Gomez, MV | 1 |
| Lundberg, JO; Montenegro, MF; Weitzberg, E | 1 |
| Burnier, M; Messerli, FH | 1 |
| Jatuworapruk, K; Lertnawapan, R | 1 |
| Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK | 1 |
| Calogiuri, G; Congedo, M; Foti, C; Macchia, L; Nettism, E; Vacca, A | 1 |
| Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB | 1 |
64 review(s) available for thiazoles and febuxostat
| Article | Year |
|---|---|
[Development antihyperuricemic candidates].
Topics: Animals; Drug Design; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Pyrazoles; Tetrazoles; Thiazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2003 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Losartan; Pyrazoles; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid; Xanthine Oxidase | 2004 |
Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Topics: Disease Management; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2005 |
An update on the treatment options for gout and calcium pyrophosphate deposition.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chondrocalcinosis; Colchicine; Drug Combinations; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Multicenter Studies as Topic; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2005 |
Newer therapeutic approaches: gout.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Febuxostat; Humans; Thiazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2006 |
New developments in clinically relevant mechanisms and treatment of hyperuricemia.
Topics: Febuxostat; Humans; Hyperuricemia; Prognosis; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2006 |
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Topics: Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2006 |
Uricase and other novel agents for the management of patients with treatment-failure gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiazoles; Treatment Failure; Urate Oxidase; Uric Acid | 2007 |
Hyperuricemia and gout: new insights into pathogenesis and treatment.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Thiazoles; Urate Oxidase; Uric Acid | 2007 |
[Inhibitors of xanthine oxidoreductase].
Topics: Allopurinol; Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyrazoles; Pyridines; Thiazoles; Xanthine Dehydrogenase | 2008 |
[New antihyperuricemic medicine: febuxostat, Puricase, etc].
Topics: Animals; Clinical Trials as Topic; Drug Design; Febuxostat; Gout Suppressants; Humans; Nitriles; Organic Anion Transporters; Organic Cation Transport Proteins; Polyethylene Glycols; Pyridines; Thiazoles; Urate Oxidase; Xanthine Dehydrogenase | 2008 |
Febuxostat.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Molecular Structure; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Uric Acid | 2008 |
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
Topics: Animals; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patents as Topic; Thiazoles; Xanthine Oxidase | 2007 |
Update on emerging urate-lowering therapies.
Topics: Allopurinol; Drug Discovery; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Thiazoles; United States; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2009 |
Febuxostat: a new treatment for hyperuricaemia in gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Febuxostat (Uloric) for chronic treatment of gout.
Topics: Chronic Disease; Clinical Trials as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2009 |
Febuxostat: a new agent for lowering serum urate.
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Liver Diseases; Thiazoles | 2009 |
Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Topics: Allopurinol; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Approach to the treatment of hyperuricemia.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2009 |
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Half-Life; Humans; Hyperuricemia; Thiazoles; Tissue Distribution; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 2009 |
Progress in the pharmacotherapy of gout.
Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Recombinant Fusion Proteins; Thiazoles; Uricosuric Agents | 2010 |
Management of hyperuricemia in gout: focus on febuxostat.
Topics: Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2010 |
International position paper on febuxostat.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; International Cooperation; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2010 |
New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.
Topics: Acute Disease; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Thiazoles; Urate Oxidase | 2010 |
Urate-lowering therapy for gout: focus on febuxostat.
Topics: Clinical Trials as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Thiazoles; Xanthine Oxidase | 2010 |
[The clinical picture of gout is changing].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Risk Factors; Thiazoles; Uricosuric Agents | 2010 |
Gout therapeutics: new drugs for an old disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Thiazoles; United States; United States Food and Drug Administration; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2011 |
Advances in gout: some answers, more questions.
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2010 |
Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure?
Topics: Animals; Chronic Disease; Febuxostat; Heart Failure; Humans; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2010 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Uricosuric Agents | 2010 |
Managing gout: how is it different in patients with chronic kidney disease?
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Risk Factors; Thiazoles | 2010 |
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.
Topics: Biomedical Technology; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles | 2011 |
Febuxostat for treatment of chronic gout.
Topics: Allopurinol; Animals; Chronic Disease; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2011 |
[Treatment of gout].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents | 2011 |
Managing your patient with gout: a review of treatment options.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles | 2011 |
[Febuxostat].
Topics: Allopurinol; Enzyme Activation; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Xanthine Oxidase | 2011 |
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
[New therapeutic options for gout].
Topics: Allopurinol; Controlled Clinical Trials as Topic; Drug Approval; Drugs, Investigational; Febuxostat; Gout; Gout Suppressants; Humans; Interleukin-1beta; Organic Anion Transporters; Polyethylene Glycols; Recombinant Proteins; Thiazoles; Urate Oxidase | 2011 |
Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.
Topics: Animals; Calcium Oxalate; Crystallization; Cystinuria; Drugs, Investigational; Febuxostat; Humans; Kidney; Kidney Calculi; Secondary Prevention; Thiazoles; Treatment Outcome; Uric Acid; Uricosuric Agents | 2011 |
[Gout - regardless of therapeutic options a "forgotten" disease].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Inflammasomes; Interleukin-1; Long-Term Care; Probenecid; Signal Transduction; Thiazoles; Uric Acid | 2011 |
[Hyperuricemia, gout, pseudogout and concomitant diseases].
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chondrocalcinosis; Comorbidity; Diabetes Mellitus, Type 2; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Kidney Failure, Chronic; Thiazoles; Xanthine Oxidase | 2011 |
Recent advances in management of gout.
Topics: Adrenal Cortex Hormones; Alcohol Drinking; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Ascorbic Acid; Colchicine; Comorbidity; Cryotherapy; Diet; Dose-Response Relationship, Drug; Febuxostat; Fructose; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Purines; Receptors, Interleukin-1; Recombinant Fusion Proteins; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Vitamins; Xanthine Oxidase | 2012 |
[Pharmacological sheet. Febuxostat, oral (Adenuric)].
Topics: Contraindications; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2012 |
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Comorbidity; Contraindications; Febuxostat; Glucocorticoids; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Probenecid; PubMed; Renal Insufficiency, Chronic; Secondary Prevention; Thiazoles; Urate Oxidase | 2012 |
[Gout: an overview of available urate lowering therapies].
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Guidelines as Topic; Humans; Organ Transplantation; Polyethylene Glycols; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2012 |
[Gout and other crystal-induced arthritides].
Topics: Absorptiometry, Photon; Aged; Allopurinol; Arthritis, Gouty; Chondrocalcinosis; Cross-Sectional Studies; Enzymes, Immobilized; Evidence-Based Medicine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Risk Factors; Thiazoles; Ultrasonography; Urate Oxidase | 2012 |
Evaluation and treatment of gout as a chronic disease.
Topics: Arthritis, Gouty; Chronic Disease; Disease Progression; Evaluation Studies as Topic; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid | 2012 |
Safety of urate-lowering therapies: managing the risks to gain the benefits.
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Thiazoles; Uric Acid | 2012 |
Febuxostat for treating chronic gout.
Topics: Allopurinol; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Randomized Controlled Trials as Topic; Thiazoles | 2012 |
Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Febuxostat; Heart Failure; Humans; Inflammation; Ischemia; Rabbits; Rats; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2013 |
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2013 |
[The cutting-edge of medicine; role of hyperuricemia in cardiorenal syndrome].
Topics: Cardio-Renal Syndrome; Febuxostat; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome | 2013 |
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Tumor lysis syndrome: new challenges and recent advances.
Topics: Acute Kidney Injury; Allopurinol; Bicarbonates; Buffers; Calcium; Diuretics; Enzyme Inhibitors; Febuxostat; Fluid Therapy; Humans; Hyperkalemia; Hyperphosphatemia; Hyperuricemia; Hypocalcemia; Renal Dialysis; Thiazoles; Tumor Lysis Syndrome; Urate Oxidase | 2014 |
Safety profile of anti-gout agents: an update.
Topics: Allopurinol; Colchicine; Drug Interactions; Febuxostat; Gout; Gout Suppressants; HLA-B Antigens; Humans; Interleukin-1; Polyethylene Glycols; Risk Factors; Safety; Thiazoles; Urate Oxidase | 2014 |
Febuxostat: drug review and update.
Topics: Animals; Arthritis, Gouty; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hepatic Insufficiency; Humans; Hyperuricemia; Liver; Thiazoles; Xanthine Oxidase | 2014 |
Therapeutic approaches to chronic hyperuricemia and gout.
Topics: Allopurinol; Cardiovascular Diseases; Chronic Disease; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Life Style; Patient Education as Topic; Thiazoles; Xanthine Oxidase | 2014 |
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Febuxostat; Feeding Behavior; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Risk Reduction Behavior; Thiazoles; Urate Oxidase; Uricosuric Agents | 2014 |
Emerging therapies for gout.
Topics: Acetamides; Adrenocorticotropic Hormone; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Benzodiazepines; Febuxostat; Gout; Gout Suppressants; Humans; Imino Furanoses; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Melanocortins; Phenylacetates; Polyethylene Glycols; Pyrimidinones; Recombinant Fusion Proteins; Thiazoles; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents | 2014 |
Clinical inquiry: Which prophylactic therapies best prevent gout attacks?
Topics: Allopurinol; Colchicine; Evidence-Based Medicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Quality of Life; Thiazoles; Urate Oxidase | 2014 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2014 |
Advances in pharmacotherapy for the treatment of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzbromarone; Clinical Trials, Phase III as Topic; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Probenecid; Thiazoles; Urate Oxidase; Uric Acid | 2015 |
Febuxostat for the treatment of gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Xanthine Oxidase | 2015 |
[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid | 2014 |
46 trial(s) available for thiazoles and febuxostat
| Article | Year |
|---|---|
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Topics: Adult; Area Under Curve; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Humans; Liver; Male; Placebos; Purines; Thiazoles; Time Factors; Uric Acid; Xanthine Oxidase | 2004 |
PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Topics: Area Under Curve; Enzyme Inhibitors; Febuxostat; Female; Humans; Kidney; Kidney Diseases; Male; Renal Insufficiency; Thiazoles; Time Factors; Xanthine Oxidase | 2004 |
Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Topics: Area Under Curve; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Male; Oxygen; Thiazoles; Time Factors; Xanthine Dehydrogenase; Xanthine Oxidase | 2004 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Topics: Administration, Oral; Adult; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Febuxostat; Female; Humans; Liver Diseases; Male; Middle Aged; Thiazoles; Xanthine Oxidase | 2006 |
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cross-Over Studies; Drug Interactions; Febuxostat; Female; Gout Suppressants; Humans; Indomethacin; Male; Metabolic Clearance Rate; Middle Aged; Naproxen; Reference Values; Thiazoles | 2006 |
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypoxanthine; Male; Models, Biological; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase | 2006 |
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
Topics: Adult; Antacids; Cross-Over Studies; Dietary Fats; Drug Interactions; Fasting; Febuxostat; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Thiazoles | 2008 |
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Linear Models; Multivariate Analysis; Odds Ratio; Thiazoles; Time Factors; Treatment Outcome | 2008 |
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Biotransformation; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypoxanthine; Male; Protein Binding; Sex Factors; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase; Young Adult | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2008 |
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Topics: Adult; Aged; Biomarkers; Clinical Trials, Phase II as Topic; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Joints; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2009 |
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Chromatography, High Pressure Liquid; Febuxostat; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Xanthine Oxidase; Young Adult | 2011 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult | 2010 |
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hydrochlorothiazide; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase; Young Adult | 2010 |
Renal function in gout: long-term treatment effects of febuxostat.
Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Thiazoles; Young Adult | 2011 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2010 |
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Japan; Kidney Diseases, Cystic; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Oxypurinol; Renal Insufficiency; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2011 |
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Illinois; Male; Metabolic Diseases; Middle Aged; Obesity; Retrospective Studies; Sex Factors; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2012 |
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Liver Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2011 |
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP2C8; Double-Blind Method; Drug Interactions; Febuxostat; Female; Gout Suppressants; Half-Life; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Rosiglitazone; Substrate Specificity; Thiazoles; Thiazolidinediones; Young Adult | 2012 |
African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Black or African American; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; White People; Young Adult | 2012 |
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2012 |
The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Male; Middle Aged; Theophylline; Thiazoles; Xanthine Oxidase | 2012 |
Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
Topics: Allopurinol; Cardiovascular Diseases; Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies; Thiazoles | 2012 |
Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Topics: Aged; Albuminuria; Allopurinol; Arachidonic Acid; Blood Pressure; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, LDL; Male; Middle Aged; Pulse Wave Analysis; Stroke Volume; Thiazoles; Uric Acid | 2013 |
Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Body Mass Index; Cohort Studies; Comorbidity; Diabetes Complications; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Intention to Treat Analysis; Kidney; Lost to Follow-Up; Male; Middle Aged; Obesity; Patient Dropouts; Renal Insufficiency; Thiazoles; Xanthine Oxidase; Young Adult | 2013 |
Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
Topics: Adult; Allopurinol; Biomarkers; Calcium Oxalate; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Humans; Male; Middle Aged; Multidetector Computed Tomography; Thiazoles; Time Factors; Treatment Outcome; United States; Uric Acid; Urinary Calculi; Xanthine Oxidase | 2013 |
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Topics: Aged; Allopurinol; Biomarkers; Chronic Disease; Enzyme Inhibitors; Febuxostat; Germany; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Inflammation Mediators; Kidney; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pulse Wave Analysis; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Vascular Stiffness; Xanthine Oxidase | 2014 |
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Prevalence; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Topics: Administration, Oral; Biomarkers; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Japan; Kidney; Prospective Studies; Renal Insufficiency, Chronic; Research Design; Risk Factors; Severity of Illness Index; Tablets; Thiazoles; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2014 |
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Remission Induction; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Thioglycolates; Triazoles; Uric Acid | 2014 |
Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.
Topics: Allopurinol; Biomarkers; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hypertension, Renal; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Thiazoles; Treatment Outcome | 2014 |
Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
Topics: Adult; Area Under Curve; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Half-Life; Healthy Volunteers; Humans; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Republic of Korea; Therapeutic Equivalency; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2015 |
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Neoplasms; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine Oxidase; Young Adult | 2016 |
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Pulse Wave Analysis; Risk Factors; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
128 other study(ies) available for thiazoles and febuxostat
| Article | Year |
|---|---|
Determination of plasma purine nucleoside phosphorylase activity by high-performance liquid chromatography.
Topics: Adult; Aged; Asthma; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypoxanthine; Hypoxanthines; Inosine; Male; Middle Aged; Purine-Nucleoside Phosphorylase; Thiazoles; Uric Acid; Xanthine Oxidase | 1995 |
Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
Topics: Administration, Oral; Allopurinol; Animals; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Macaca mulatta; Male; Pan troglodytes; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase; Xanthines | 1993 |
Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
Topics: Allantoin; Allopurinol; Animals; Cattle; Febuxostat; Gout Suppressants; Male; Mice; Mice, Inbred ICR; Rats; Rats, Sprague-Dawley; Thiazoles; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 1993 |
Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.
Topics: Allopurinol; Biological Transport; Carrier Proteins; Drug Interactions; Enzyme Inhibitors; Febuxostat; Humans; Hypoxanthine; Inosine; Lung Neoplasms; Membrane Proteins; Nucleoside Transport Proteins; Nucleosides; Pentosyltransferases; Purines; Pyrimidine Phosphorylases; Thiazoles; Tumor Cells, Cultured; Uracil; Uridine; Xanthine; Xanthine Oxidase | 2000 |
Nephrotoxic effects of allopurinol in dinitrofluorobenzene-sensitized mice: comparative studies on TEI-6720.
Topics: Acute Kidney Injury; Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Dermatitis, Contact; Dinitrofluorobenzene; Enzyme Inhibitors; Febuxostat; Liver; Male; Mice; Mice, Inbred BALB C; Thiazoles; Xanthine Oxidase | 1999 |
A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Topics: Allantoin; Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Kidney Calculi; Male; Rats; Rats, Inbred Strains; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase | 1999 |
An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
Topics: Animals; Cattle; Crystallography, X-Ray; Enzyme Inhibitors; Febuxostat; Kinetics; Milk; Models, Molecular; Molecular Structure; Spectrometry, Fluorescence; Thiazoles; Xanthine Dehydrogenase | 2003 |
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Topics: Animals; Enzyme Inhibitors; Febuxostat; Kinetics; Milk; Molecular Structure; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2005 |
Febuxostat (Teijin/Ipsen/TAP).
Topics: Animals; Drug Evaluation, Preclinical; Enzyme Inhibitors; Febuxostat; Gout; Humans; Patents as Topic; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Thiazoles; Xanthine Oxidase | 2005 |
Febuxostat--treatment for hyperuricemia and gout?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
Febuxostat versus allopurinol for gout.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Refusal; Xanthine Oxidase | 2006 |
Febuxostat versus allopurinol for gout.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Refusal; Xanthine Oxidase | 2006 |
Gout's not just for the gluttonous.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Risk Factors; Sex Factors; Socioeconomic Factors; Thiazoles; Uric Acid | 2006 |
[Febuxostat versus allopurinol for hyperuricemia].
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles | 2006 |
Case 8: initiation of urate-lowering therapy for standard advanced gout.
Topics: Arthritis, Gouty; Febuxostat; Humans; Male; Middle Aged; Oxypurinol; Thiazoles; Uric Acid; Uricosuric Agents | 2006 |
Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure.
Topics: Animals; Blood Pressure; Cardiac Pacing, Artificial; Dogs; Febuxostat; Heart Diseases; Thiazoles; Ventricular Function, Left; Xanthine Oxidase | 2006 |
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Topics: Animals; Blood Pressure; Febuxostat; Follow-Up Studies; Gout Suppressants; Hypertension, Renal; Hyperuricemia; Kidney Glomerulus; Male; Oxonic Acid; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazoles; Uric Acid; Xanthine Oxidase | 2008 |
Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.
Topics: Allopurinol; Animals; Body Weight; Echocardiography; Enzyme Inhibitors; Febuxostat; Heart Failure; Male; Myocardial Infarction; Myocardium; Organ Size; Rabbits; Thiazoles; Time Factors; Xanthine Oxidase | 2008 |
Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.
Topics: Animals; Blood Pressure; Body Weight; Energy Intake; Febuxostat; Fructose; Gout Suppressants; Kidney; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazoles; Xanthine Oxidase | 2008 |
Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Topics: Allopurinol; Animals; Catalysis; Crystallization; Enzyme Inhibitors; Febuxostat; Molybdenum; Nitriles; Protein Conformation; Pyridines; Thiazoles; Xanthine Dehydrogenase | 2008 |
In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.
Topics: Blood Proteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Febuxostat; Glucuronosyltransferase; Humans; Ibuprofen; In Vitro Techniques; Male; Microsomes, Liver; Protein Binding; Thiazoles; Warfarin; Xanthine Oxidase | 2008 |
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Topics: Animals; Disease Models, Animal; Febuxostat; Hyperuricemia; Kidney; Kidney Failure, Chronic; Male; Microcirculation; Nephrectomy; Oxonic Acid; Rats; Rats, Wistar; Recovery of Function; Thiazoles; Treatment Outcome | 2008 |
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Febuxostat : a viewpoint by Naomi Schlesinger.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Febuxostat : a viewpoint by N. Lawrence Edwards.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Gout management: let's get it right this time.
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Drug Evaluation; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid; Xanthine Oxidase | 2008 |
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice.
Topics: Animals; Disease Models, Animal; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Systole; Thiazoles; Ventricular Dysfunction, Left | 2008 |
Febuxostat.
Topics: Chronic Disease; Drug Approval; European Union; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2009 |
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2009 |
Nickel-catalyzed biaryl coupling of heteroarenes and aryl halides/triflates.
Topics: Combinatorial Chemistry Techniques; Febuxostat; Hydrocarbons, Halogenated; Mesylates; Molecular Structure; Nickel; Thiazoles | 2009 |
New gout treatment approved.
Topics: Administration, Oral; Drug Approval; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; United States; United States Food and Drug Administration; Uric Acid; Xanthine Oxidase | 2009 |
Gout Study Group: update on hyperuricemia and gout.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Prednisone; Prevalence; Thiazoles; United States; Uric Acid | 2009 |
Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Topics: Allopurinol; Drug Approval; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
New Drugs2010, PART 1.
Topics: Acetamides; Antibodies, Monoclonal; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azepines; Benzazepines; Benzhydryl Compounds; Benzyl Alcohol; Benzylamines; Cyclams; Cyclopropanes; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Ethanolamines; Everolimus; Febuxostat; Fluorenes; Fluoroquinolones; Gout Suppressants; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Indoles; Lacosamide; Milnacipran; Oligopeptides; Phenols; Selective Serotonin Reuptake Inhibitors; Sirolimus; Tapentadol; Thiazoles; Tolvaptan; Triazoles | 2010 |
Febuxostat provides new gout treatment option.
Topics: Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2010 |
Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction.
Topics: Allopurinol; Animals; Constriction, Pathologic; Enzyme Inhibitors; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Thiazoles; Xanthine Oxidase | 2010 |
Febuxostat for gout.
Topics: Aged; Drug Costs; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Thiazoles | 2010 |
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Chronic Disease; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2010 |
[Therapy of acute gout attack. It need not always be NSAID].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2010 |
Treatment of gout.
Topics: Aged; Allopurinol; Australia; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Patient Compliance; Practice Guidelines as Topic; Prednisolone; Renal Dialysis; Thiazoles; Uric Acid | 2011 |
Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.
Topics: Allopurinol; Animals; Cattle; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Febuxostat; Glycosaminoglycans; Kinetics; Oxypurinol; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2011 |
Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstates.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adrenergic Agonists; Allopurinol; Animals; Basal Metabolism; Biopsy; Cardiotonic Agents; Coronary Circulation; Dogs; Energy Metabolism; Enzyme Inhibitors; Febuxostat; Hemodynamics; Models, Animal; Myocardial Contraction; Myocardium; Oxygen Consumption; Phosphocreatine; Reactive Oxygen Species; Thiazoles; Time Factors; Xanthine Oxidase | 2011 |
Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Resistance; Febuxostat; Female; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Failure; Treatment Outcome; Uric Acid; Young Adult | 2011 |
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Topics: Aged; Aged, 80 and over; Allopurinol; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Thiazoles; Uric Acid | 2011 |
Nickel-catalyzed C-H arylation of azoles with haloarenes: scope, mechanism, and applications to the synthesis of bioactive molecules.
Topics: Azoles; Benzoxazoles; Biological Products; Catalysis; Febuxostat; Nickel; Oxazoles; Pyridines; Thiazoles | 2011 |
Gout and transplantation: new treatment option-same old drug interaction.
Topics: Aged; Azathioprine; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Thiazoles | 2011 |
Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique.
Topics: Chromatography, Liquid; Drug Contamination; Febuxostat; Gout Suppressants; Humans; Tandem Mass Spectrometry; Thiazoles | 2011 |
Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.
Topics: Adult; Catastrophic Illness; Drug Therapy, Combination; Febuxostat; Glycogen Storage Disease Type I; Gout; Gout Suppressants; Humans; Magnetic Resonance Imaging; Male; Obesity, Morbid; Paraplegia; Prednisone; Probenecid; Radiography; Synovial Fluid; Thiazoles; Uric Acid | 2011 |
Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.
Topics: Allopurinol; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Making; Decision Trees; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2012 |
Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.
Topics: Animals; Cell Movement; Cytokines; Disease Models, Animal; Febuxostat; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Nephritis, Interstitial; Oxidative Stress; Rats; Rats, Sprague-Dawley; Thiazoles; Transforming Growth Factor beta; Ureteral Obstruction; Xanthine Oxidase | 2012 |
Febuxostat hypersensitivity.
Topics: Aged; Drug Hypersensitivity; Erythema; Fatigue; Febuxostat; Female; Gout; Gout Suppressants; Humans; Pruritus; Thiazoles; Withholding Treatment | 2012 |
Determination of febuxostat in human plasma using ultra-performance liquid chromatography tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Monitoring; Febuxostat; Gout Suppressants; Humans; Limit of Detection; Liquid-Liquid Extraction; Tandem Mass Spectrometry; Thiazoles; Time Factors | 2013 |
Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics.
Topics: Animals; Cattle; Enzyme Inhibitors; Febuxostat; Models, Molecular; Molecular Dynamics Simulation; Rhodobacter capsulatus; Thiazoles; Xanthine Dehydrogenase | 2012 |
Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Topics: Allopurinol; Chronic Disease; Contraindications; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Probenecid; Thiazoles | 2012 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma.
Topics: Chromatography, Liquid; Drug Stability; Febuxostat; Humans; Least-Squares Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thiazoles | 2013 |
[Medication of the month. Febuxostat (Adenuric)].
Topics: Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2012 |
Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in dog plasma and its application to a pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Drug Stability; Febuxostat; Linear Models; Liquid-Liquid Extraction; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2013 |
Casebook consults: improving outcomes in gout (multimedia activity).
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Long-Term Care; Medication Adherence; Referral and Consultation; Thiazoles; Uric Acid | 2012 |
Adherence to uric acid treatment guidelines in a rheumatology clinic.
Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Humans; Male; Middle Aged; Probenecid; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2012 |
Pharmacokinetics of febuxostat in healthy Chinese volunteers.
Topics: Administration, Oral; Asian People; Febuxostat; Female; Food-Drug Interactions; Gout Suppressants; Humans; Indicators and Reagents; Male; Sex Characteristics; Thiazoles; Xanthine Oxidase; Young Adult | 2012 |
Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Topics: Animals; Apoptosis; Endoplasmic Reticulum Stress; Febuxostat; Hyperuricemia; Kidney; Kidney Tubules; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2012 |
Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats.
Topics: Alanine Transaminase; Allopurinol; Animals; Aspartate Aminotransferases; Dose-Response Relationship, Drug; Febuxostat; Gout Suppressants; Intestinal Mucosa; Lipid Peroxidation; Lung; Male; Malondialdehyde; Muscle Contraction; Muscle, Smooth; Peroxidase; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazoles; Tumor Necrosis Factor-alpha; Xanthine Dehydrogenase; Xanthine Oxidase | 2013 |
Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules.
Topics: Allopurinol; Animals; Desensitization, Immunologic; Drug Hypersensitivity; Febuxostat; Gout; Humans; Hyperuricemia; Product Surveillance, Postmarketing; Recombinant Proteins; Skin; Thiazoles; Urate Oxidase | 2013 |
Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.
Topics: Aged; Aged, 80 and over; Biomarkers; Drug Monitoring; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Thiazoles; Time Factors; Treatment Outcome; Uric Acid | 2013 |
Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Child; Data Mining; Febuxostat; Female; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Thromboembolism; United States; United States Food and Drug Administration | 2013 |
Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Topics: Animals; Blood Pressure; Desoxycorticosterone; Febuxostat; Hypertension; Male; Rats; Rats, Sprague-Dawley; Thiazoles; Xanthine Oxidase | 2013 |
[Case presentation--tophaceous gout].
Topics: Aged, 80 and over; Arthritis, Gouty; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Gout Suppressants; Hand Deformities, Acquired; Humans; Hyperuricemia; Mobility Limitation; Thiazoles; Uric Acid | 2012 |
Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Neutropenia; Renal Insufficiency, Chronic; Thiazoles | 2013 |
Italian Society of Rheumatology recommendations for the management of gout.
Topics: Adrenal Cortex Hormones; Advisory Committees; Alcoholic Beverages; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Combined Modality Therapy; Dairy Products; Disease Management; Evidence-Based Medicine; Febuxostat; Female; Fructose; Gout; Humans; Italy; Male; Risk Factors; Smoking; Societies, Medical; Thiazoles; Uric Acid | 2013 |
Cost-effectiveness of febuxostat in chronic gout.
Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiazoles; Uric Acid | 2014 |
A sensitive LC-MS/MS method for the quantification of febuxostat in human plasma and its pharmacokinetic application.
Topics: Chromatography, High Pressure Liquid; Febuxostat; Gout Suppressants; Humans; Limit of Detection; Liquid-Liquid Extraction; Male; Tandem Mass Spectrometry; Thiazoles; Xanthine Oxidase | 2013 |
Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.
Topics: Allopurinol; Ambulatory Care; Colchicine; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Middle Aged; Office Visits; Thiazoles | 2013 |
Development of a simple LC-MS/MS method for the determination of febuxostat in human plasma and its application to a bioequivalence study.
Topics: Adult; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Half-Life; Humans; Male; Mass Spectrometry; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Therapeutic Equivalency; Thiazoles; Xanthine Oxidase | 2013 |
Pegloticase for treatment of tophaceous polyarticular gout.
Topics: Adult; Arthritis, Gouty; Febuxostat; Gout Suppressants; Humans; Male; Polyethylene Glycols; Thiazoles; Urate Oxidase; Uric Acid | 2013 |
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis.
Topics: Animals; Axons; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Febuxostat; Female; Mice; Multiple Sclerosis; Myelin Sheath; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2013 |
Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK.
Topics: Animals; Cell Line, Tumor; Chemokine CCL2; Dual Specificity Phosphatase 1; Febuxostat; Female; Humans; Inflammation; Lipopolysaccharides; Macrophages; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Phosphorylation; Reactive Oxygen Species; RNA, Messenger; Thiazoles; Xanthine Oxidase | 2013 |
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid | 2014 |
Irregular gout.
Topics: Chelating Agents; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Lead Poisoning; Male; Occupational Diseases; Occupational Exposure; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Young Adult | 2014 |
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medication Adherence; Primary Health Care; Risk Factors; Severity of Illness Index; Thiazoles; United States; Uric Acid | 2014 |
Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Endothelium, Vascular; Febuxostat; Male; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiazoles | 2014 |
New urea and thiourea derivatives of piperazine doped with febuxostat: synthesis and evaluation of anti-TMV and antimicrobial activities.
Topics: Anti-Infective Agents; Antiviral Agents; Bacterial Physiological Phenomena; Febuxostat; Piperazine; Piperazines; Thiazoles; Thiourea; Tobacco Mosaic Virus; Urea | 2013 |
Pharmacokinetic interaction between febuxostat and morin in rats.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Dietary Supplements; Dose-Response Relationship, Drug; Drug Interactions; Febuxostat; Flavonoids; Half-Life; Male; Rats; Rats, Wistar; Thiazoles | 2014 |
Febuxostat as a novel option to optimize thiopurines' metabolism in patients with inadequate metabolite levels.
Topics: Adult; Azathioprine; Drug Interactions; Enzyme Inhibitors; Febuxostat; Female; Guanine Nucleotides; Humans; Immunosuppressive Agents; Mercaptopurine; Muscular Diseases; Thiazoles; Thionucleotides; Xanthine Oxidase | 2014 |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Topics: Adult; Aged; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Thiazoles; Uric Acid; Xanthine Oxidase | 2014 |
Febuxostat: hepatic failure.
Topics: Febuxostat; Gout Suppressants; Humans; Liver Failure; Thiazoles; Xanthine Oxidase | 2013 |
Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease.
Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic; Rhabdomyolysis; Thiazoles | 2014 |
Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure.
Topics: Adrenal Cortex Hormones; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Drug Therapy, Combination; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2014 |
Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Thiazoles; Xanthine Oxidase | 2014 |
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
Topics: Aged; Allopurinol; Black or African American; Evaluation Studies as Topic; Febuxostat; Female; Focus Groups; Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Thiazoles; Uric Acid | 2014 |
Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Comparative Effectiveness Research; Drug Administration Schedule; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2014 |
Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Cholesterol; Cytokines; Disease Models, Animal; Endothelial Cells; Febuxostat; Gout Suppressants; Inflammation; L-Lactate Dehydrogenase; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2014 |
Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.
Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Hospitalization; Humans; Hyperuricemia; Male; Prevalence; Thiazoles; Xanthine Oxidase | 2014 |
Treat to target in gout by combining two modes of action.
Topics: Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Thioglycolates; Triazoles | 2014 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis | 2014 |
Screening for selective inhibitors of xanthine oxidase from Flos Chrysanthemum using ultrafiltration LC-MS combined with enzyme channel blocking.
Topics: Apigenin; Catalytic Domain; Chromatography, Liquid; Chrysanthemum; Drugs, Chinese Herbal; Enzyme Inhibitors; Febuxostat; Flavones; Flowers; Glucosides; Gout Suppressants; Luteolin; Mass Spectrometry; Thiazoles; Ultrafiltration; Xanthine Oxidase | 2014 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Febuxostat in adenosine phosphoribosyltransferase deficiency.
Topics: Adenine Phosphoribosyltransferase; Adult; Febuxostat; Female; Humans; Metabolism, Inborn Errors; Thiazoles; Urolithiasis | 2014 |
Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Endpoint Determination; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2014 |
Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Antibiotics, Antineoplastic; Cyclooxygenase 2; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ectodysplasins; Febuxostat; Gout Suppressants; Kidney; Liver; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2014 |
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Disease Progression; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
Efficacy and safety of febuxostat in elderly female patients.
Topics: Aged; Comorbidity; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Retrospective Studies; Thiazoles; Treatment Outcome | 2014 |
An HPLC-MS/MS method for simultaneous determination of the active metabolites of febuxostat (67M-1, 67M-2 and 67M-4) in human plasma.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Febuxostat; Female; Humans; Linear Models; Male; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2014 |
Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry.
Topics: Aged; Aged, 80 and over; Allopurinol; Cross-Sectional Studies; Febuxostat; Female; Gout Suppressants; Hospitals; Humans; Hyperuricemia; Inappropriate Prescribing; Italy; Male; Patient Admission; Patient Discharge; Registries; Risk; Thiazoles; Xanthine Oxidase | 2014 |
Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients?
Topics: Aged; Cholesterol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Triglycerides | 2014 |
Cost-effectiveness of allopurinol and febuxostat for the management of gout.
Topics: Allopurinol; Cost Savings; Cost-Benefit Analysis; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Markov Chains; Models, Theoretical; Quality-Adjusted Life Years; Thiazoles | 2014 |
The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Death; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Gastroesophageal Reflux; Gout Suppressants; Liver; Lung; Lung Injury; Male; Mice, Inbred C57BL; Necrosis; Neutrophil Infiltration; Peritoneum; Peritonitis; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Topics: Animals; Area Under Curve; Biological Availability; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Febuxostat; Female; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Powder Diffraction; Rats, Sprague-Dawley; Solubility; Suspensions; Thiazoles; X-Ray Diffraction | 2015 |
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Topics: Aged; Allopurinol; Antineoplastic Agents; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Humans; Hypoxanthine; Male; Middle Aged; Pilot Projects; Prospective Studies; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine; Xanthine Oxidase | 2014 |
Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Topics: Allopurinol; Chronic Disease; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Markov Chains; Thiazoles; Uric Acid | 2015 |
Quantification of febuxostat polymorphs using powder X-ray diffraction technique.
Topics: Calibration; Calorimetry, Differential Scanning; Febuxostat; Powder Diffraction; Thiazoles; X-Ray Diffraction | 2015 |
Characteristics and management of gout patients in Europe: data from a large cohort of patients.
Topics: Adult; Allopurinol; Cohort Studies; Comorbidity; Cross-Sectional Studies; Europe; Febuxostat; Female; France; Gout; Gout Suppressants; Greece; Humans; Male; Middle Aged; Obesity; Patient Compliance; Thiazoles; Uric Acid | 2015 |
Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antigens, Differentiation, T-Lymphocyte; Case-Control Studies; Cells, Cultured; Cross Reactions; Drug Eruptions; Enzyme-Linked Immunosorbent Assay; Febuxostat; Female; Humans; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Oxypurinol; Reference Values; Stevens-Johnson Syndrome; Thiazoles | 2015 |
The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Topics: Animals; Apoptosis; Choline Deficiency; Cytoprotection; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hyperuricemia; Liver; Liver Cirrhosis, Experimental; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers; Body Weight; Doxorubicin; Febuxostat; Heart; Male; Organ Size; Rats; Rats, Wistar; Superoxide Dismutase; Thiazoles; Thiobarbituric Acid Reactive Substances; Xanthine Oxidase | 2015 |
Febuxostat-associated rhabdomyolysis in chronic renal failure.
Topics: Aged; Febuxostat; Gout Suppressants; Humans; Kidney Failure, Chronic; Male; Rhabdomyolysis; Thiazoles | 2015 |
Febuxostat (Adenuric). Toxic epidermal necrolysis and severe hypersensitivity reactions added to the EU SPC.
Topics: Drug Hypersensitivity Syndrome; Febuxostat; Gout Suppressants; Humans; Risk Assessment; Risk Factors; Severity of Illness Index; Stevens-Johnson Syndrome; Thiazoles | 2015 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat.
Topics: Enzyme Inhibitors; Febuxostat; Gout Suppressants; Humans; Thiazoles; Xanthine Oxidase | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?
Topics: Cardiovascular Diseases; Drug Labeling; Febuxostat; Humans; Thiazoles; Uric Acid | 2019 |
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Thailand; Thiazoles; Treatment Outcome; Uric Acid | 2021 |
Hypersensitivity to Febuxostat in a Patient with a Previous Allopurinolinduced Steven-Johnson Syndrome: A Case Report of Treatment with a Slow Desensitization Protocol.
Topics: Adult; Febuxostat; Gout; Gout Suppressants; Humans; Hypersensitivity; Male; Thiazoles | 2022 |